Trial Profile
Phase II Trial of Olaparib in Patients with Advanced Castration Resistant Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms TOPARP; TOPARP-A; TOPARP-B
- 10 Apr 2021 Results of exploratory analysis investigating the predictive value of an HRR function assay detecting RAD51 foci by immunofluorescence in tumor biopsies presented at the 112th Annual Meeting of the American Association for Cancer Research
- 02 Dec 2019 Results presented in The Institute of Cancer Research Media Release.
- 02 Dec 2019 According to The Institute of Cancer Research media release, this trial was funded in part by olaparib's manufacturer, AstraZeneca, plus by Cancer Research UK, Prostate Cancer UK, the Prostate Cancer Foundation, Movember and the Experimental Cancer Medicine Centre (ECMC) Network.